BR0317280A - Prevenção e tratamento do mal de alzheimer - Google Patents
Prevenção e tratamento do mal de alzheimerInfo
- Publication number
- BR0317280A BR0317280A BR0317280-5A BR0317280A BR0317280A BR 0317280 A BR0317280 A BR 0317280A BR 0317280 A BR0317280 A BR 0317280A BR 0317280 A BR0317280 A BR 0317280A
- Authority
- BR
- Brazil
- Prior art keywords
- alzheimer
- treatment
- prevention
- inhibitor
- disease
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 229940121773 Secretase inhibitor Drugs 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215722A FR2848452B1 (fr) | 2002-12-12 | 2002-12-12 | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
| PCT/FR2003/003654 WO2004062652A1 (fr) | 2002-12-12 | 2003-12-10 | Application et traitement de la maladie d'alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317280A true BR0317280A (pt) | 2005-11-08 |
Family
ID=32338722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317280-5A BR0317280A (pt) | 2002-12-12 | 2003-12-10 | Prevenção e tratamento do mal de alzheimer |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1572174A1 (enExample) |
| JP (1) | JP2006514063A (enExample) |
| KR (1) | KR20050084250A (enExample) |
| CN (1) | CN1726016A (enExample) |
| AR (1) | AR042354A1 (enExample) |
| AU (1) | AU2003296802A1 (enExample) |
| BR (1) | BR0317280A (enExample) |
| CA (1) | CA2507945A1 (enExample) |
| CO (1) | CO5700712A2 (enExample) |
| FR (1) | FR2848452B1 (enExample) |
| HR (1) | HRP20050534A2 (enExample) |
| MA (1) | MA27500A1 (enExample) |
| MX (1) | MXPA05005556A (enExample) |
| NO (1) | NO20053341L (enExample) |
| NZ (1) | NZ540496A (enExample) |
| PE (1) | PE20040770A1 (enExample) |
| PL (1) | PL377110A1 (enExample) |
| RS (1) | RS20050420A (enExample) |
| RU (1) | RU2005121909A (enExample) |
| TW (1) | TW200503707A (enExample) |
| WO (1) | WO2004062652A1 (enExample) |
| ZA (1) | ZA200504656B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| ZA200603165B (en) | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| CN1918131B (zh) | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶抑制剂 |
| CA2589102C (en) | 2004-11-02 | 2013-08-13 | Northwestern University | Pyridazine compounds and methods for using the compounds to treat inflammatory diseases |
| EP2015750A2 (en) | 2006-04-28 | 2009-01-21 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| PL2157973T3 (pl) * | 2007-05-22 | 2015-12-31 | Otsuka Pharma Co Ltd | Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera |
| AU2012328453B2 (en) * | 2011-10-28 | 2017-05-04 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| ES2633766T3 (es) * | 2011-10-28 | 2017-09-25 | Lumena Pharmaceuticals Llc | Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2040996A1 (en) * | 1990-05-02 | 1991-11-03 | Robert L. Albright | Composition and method for controlling cholesterol |
| AU668682B2 (en) * | 1991-02-22 | 1996-05-16 | Howard K. Shapiro | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| EP0910351A1 (en) * | 1996-06-27 | 1999-04-28 | G.D. Searle & Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| NZ505761A (en) * | 1998-01-28 | 2003-08-29 | Warner Lambert Co | Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis |
| US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
| DE19825804C2 (de) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19845405C2 (de) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
| WO2001056579A1 (en) * | 2000-02-04 | 2001-08-09 | Esperion Therapeutics Inc. | Methods for treating alzheimer's disease |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
-
2002
- 2002-12-12 FR FR0215722A patent/FR2848452B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-10 MX MXPA05005556A patent/MXPA05005556A/es not_active Application Discontinuation
- 2003-12-10 PL PL377110A patent/PL377110A1/pl not_active Application Discontinuation
- 2003-12-10 CN CNA2003801059727A patent/CN1726016A/zh active Pending
- 2003-12-10 CA CA002507945A patent/CA2507945A1/fr not_active Abandoned
- 2003-12-10 RU RU2005121909/15A patent/RU2005121909A/ru not_active Application Discontinuation
- 2003-12-10 RS YUP-2005/0420A patent/RS20050420A/sr unknown
- 2003-12-10 PE PE2003001247A patent/PE20040770A1/es not_active Application Discontinuation
- 2003-12-10 AU AU2003296802A patent/AU2003296802A1/en not_active Abandoned
- 2003-12-10 BR BR0317280-5A patent/BR0317280A/pt not_active IP Right Cessation
- 2003-12-10 HR HR20050534A patent/HRP20050534A2/xx not_active Application Discontinuation
- 2003-12-10 JP JP2004566119A patent/JP2006514063A/ja not_active Abandoned
- 2003-12-10 EP EP03815109A patent/EP1572174A1/fr not_active Withdrawn
- 2003-12-10 KR KR1020057010595A patent/KR20050084250A/ko not_active Withdrawn
- 2003-12-10 NZ NZ540496A patent/NZ540496A/en unknown
- 2003-12-10 AR ARP030104540A patent/AR042354A1/es not_active Application Discontinuation
- 2003-12-10 WO PCT/FR2003/003654 patent/WO2004062652A1/fr not_active Ceased
- 2003-12-11 TW TW092134949A patent/TW200503707A/zh unknown
-
2005
- 2005-06-07 ZA ZA200504656A patent/ZA200504656B/en unknown
- 2005-06-09 CO CO05056010A patent/CO5700712A2/es not_active Application Discontinuation
- 2005-06-10 MA MA28329A patent/MA27500A1/fr unknown
- 2005-07-08 NO NO20053341A patent/NO20053341L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2507945A1 (fr) | 2004-07-29 |
| AU2003296802A1 (en) | 2004-08-10 |
| PE20040770A1 (es) | 2004-12-10 |
| NZ540496A (en) | 2008-04-30 |
| RU2005121909A (ru) | 2006-01-20 |
| WO2004062652A1 (fr) | 2004-07-29 |
| FR2848452A1 (fr) | 2004-06-18 |
| KR20050084250A (ko) | 2005-08-26 |
| TW200503707A (en) | 2005-02-01 |
| MXPA05005556A (es) | 2005-07-26 |
| AR042354A1 (es) | 2005-06-15 |
| RS20050420A (sr) | 2007-04-10 |
| HRP20050534A2 (en) | 2006-11-30 |
| MA27500A1 (fr) | 2005-08-01 |
| EP1572174A1 (fr) | 2005-09-14 |
| JP2006514063A (ja) | 2006-04-27 |
| ZA200504656B (en) | 2006-08-30 |
| PL377110A1 (pl) | 2006-01-23 |
| NO20053341L (no) | 2005-09-07 |
| CO5700712A2 (es) | 2006-11-30 |
| FR2848452B1 (fr) | 2007-04-06 |
| NO20053341D0 (no) | 2005-07-08 |
| CN1726016A (zh) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1509232E (pt) | Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer | |
| BR0312933A (pt) | Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica | |
| BR9916567A (pt) | Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares | |
| BR0206654A (pt) | Combinações de ativador(es) de receptor ativado por proliferação de peroxisoma (ppar) e inibidor(es) de absorção de esterol e tratamentos para indicações vasculares | |
| CY1110188T1 (el) | Αντισωματα κατα συζυγων φωσφορυλχολινης | |
| BRPI0413363A (pt) | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase | |
| BR0312421A (pt) | Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos | |
| BRPI0412439A (pt) | compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições | |
| BRPI0407993A (pt) | inibidores de p38 e métodos para uso dos mesmos | |
| DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| EP1824442A4 (en) | PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FROM THE GARCINIA MANGOSTANA L PLANT | |
| EA200900073A1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| BR0317280A (pt) | Prevenção e tratamento do mal de alzheimer | |
| NO20075801L (no) | Fremgangsmate til a behandle eller forhindre bennedbrytning eller osteoporose | |
| EP1708719A4 (en) | AQUEOUS PHARMACEUTICAL COMPOSITIONS OF 2,6-DIISOPROPYLPHENOL (PROPOFOL) AND THEIR USE | |
| BRPI0515776A (pt) | auxiliares de retenção e drenagem | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| EP2862867A3 (en) | Methods and compositions for the treatment of Marfan syndrome and associated disorders | |
| EP1865972A4 (en) | TREATMENT OR PREVENTION OF CANCER AND PRECCOLAR DISEASES | |
| BR0315355A (pt) | Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, composição farmacêutica e utilização de um inibidor de re-apreensão de norepinefrina | |
| NO20076566L (no) | Ny fremgangsmate for behandling av hyperlipidemi | |
| BRPI0519919A2 (pt) | composições farmacêuticas compreendendo inibidores da nep, inibidores do sistema de produção de endotelina endógena e inibidores da hmg coa redutase | |
| BR0309406A (pt) | Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento | |
| TW200806293A (en) | Methods of treatment with CETP inhibitors | |
| WO2008137636A3 (en) | Compositions and methods for identifying and treating subjects at risk of developing type 2 diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |